Treatment of ocular diseases

Abstract

Disclosed are methods for treating eye diseases or conditions characterized by vascular instability, vascular leakage and neovacularization such as diabetic macular edema, age-related macular edema, choroidal neovascularization, diabetic retinopathy, trauma, ocular ischemia, retinal angiomatous proliferation, macular telangiectasia and uveitis.

1 - 20 . (canceled) 
     
     
         21 . A method for reducing neovascularization in a subject in need thereof, the method comprising administering to the subject a therapeutically-effective amount of a monoclonal antibody, or an antigen-binding fragment thereof, wherein the monoclonal antibody, or the antigen-binding fragment thereof, inhibits a phosphatase activity of a phosphatase. 
     
     
         22 . The method of  claim 21 , wherein the phosphatase is a tyrosine phosphatase. 
     
     
         23 . The method of  claim 21 , wherein the phosphatase is human protein tyrosine phosphatase beta (HPTP-β). 
     
     
         24 . The method of  claim 21 , wherein the reducing neovascularization occurs in an eye of the subject. 
     
     
         25 . The method of  claim 21 , wherein the subject has an ocular disorder. 
     
     
         26 . The method of  claim 25 , wherein the ocular disorder is ocular edema. 
     
     
         27 . The method of  claim 25 , wherein the ocular disorder is diabetic macular edema. 
     
     
         28 . The method of  claim 25 , wherein the ocular disorder is wet age-related macular degeneration. 
     
     
         29 . The method of  claim 25 , wherein the ocular disorder is retinal vein occlusion. 
     
     
         30 . The method of  claim 25 , wherein the ocular disorder is diabetic retinopathy. 
     
     
         31 . The method of  claim 21 , wherein the monoclonal antibody or the antigen-binding fragment thereof is administered by intraocular injection. 
     
     
         32 . The method of  claim 21 , wherein the monoclonal antibody or the antigen-binding fragment thereof is administered by subcutaneous injection. 
     
     
         33 . The method of  claim 21 , wherein the monoclonal antibody or the antigen-binding fragment thereof is administered by intravenous injection. 
     
     
         34 . The method of  claim 21 , wherein the therapeutically-effective amount is from about 0.01 mg/kg to about 10 mg/kg by weight of the subject. 
     
     
         35 . The method of  claim 21 , wherein the monoclonal antibody or the antigen-binding fragment thereof is conjugated to a vehicle. 
     
     
         36 . The method of  claim 35 , wherein the vehicle is polyethylene glycol.